CN105343089A - 组合物及其在预防或治疗胰腺纤维化药物中的应用 - Google Patents
组合物及其在预防或治疗胰腺纤维化药物中的应用 Download PDFInfo
- Publication number
- CN105343089A CN105343089A CN201510662966.6A CN201510662966A CN105343089A CN 105343089 A CN105343089 A CN 105343089A CN 201510662966 A CN201510662966 A CN 201510662966A CN 105343089 A CN105343089 A CN 105343089A
- Authority
- CN
- China
- Prior art keywords
- compositions
- compound
- composition
- pancreatic gland
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 28
- 230000004761 fibrosis Effects 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 210000004907 gland Anatomy 0.000 claims description 20
- 210000000496 pancreas Anatomy 0.000 claims description 16
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 13
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 13
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 6
- 229960002591 hydroxyproline Drugs 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 6
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 210000004969 inflammatory cell Anatomy 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 238000003786 synthesis reaction Methods 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 230000002946 anti-pancreatic effect Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000035126 Facies Diseases 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- RSBNUWAVVQOBHL-UHFFFAOYSA-N C(CC)O.CC1=C(C(=O)O)C=CC=C1C(=O)O Chemical compound C(CC)O.CC1=C(C(=O)O)C=CC=C1C(=O)O RSBNUWAVVQOBHL-UHFFFAOYSA-N 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- GGLZPLKKBSSKCX-UHFFFAOYSA-N S-ethylhomocysteine Chemical compound CCSCCC(N)C(O)=O GGLZPLKKBSSKCX-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229950002366 nafoxidine Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000002705 pancreatic stellate cell Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及有机合成和药物化学领域,具体涉及组合物82092202050618、制备方法及其在制备预防或治疗胰腺纤维化药物上的用途。本发明公开了一种组合物82092202050618及其制备方法。药理学实验表明,本发明的组合物82092202050618具有预防或治疗胰腺纤维化的作用,具有开发预防或治疗胰腺纤维化药物的价值。
Description
技术领域
本发明涉及有机合成和药物化学领域,具体涉及组合物82092202050618、制备方法及其用途。
背景技术
胰腺纤维化是各种原因所致慢性胰腺炎的共同特征,同时也是与其伴随的组织病理学特点,表现为大量成纤维细胞增生和富含连接组织的细胞外基质。是多种原因导致胰腺损伤修复的结果,近期发现胰腺星状细胞和多种细胞因子与胰腺纤维化有关,胰腺纤维化目前发病率愈来愈高,急需研发高效低毒的抗胰腺纤维化药物。
胰腺纤维化的治疗目前已有的药物存在毒性大、安全性低的问题,从天然产物中寻找化合物或先导化合物并进行结构修饰获得其衍生物,从而得到高效低毒的潜在药物最有重要价值。
本发明涉及的化合物I是一个2011年发表(Fan-YuMengetal.,2011.SchiglautoneA,aNewTricyclicTriterpenoidwithaUnique6/7/9-FusedSkeletonfromtheStemsofSchisandraglaucescens.OrganicLetters13(2011)1502–1505)的化合物,我们对化合物I进行了结构修饰,获得了两个新的衍生物即化合物III和化合物IV,并用化合物III和化合物IV制备了组合物82092202050618并对该组合物抗胰腺纤维化活性进行了评价,其具有抗胰腺纤维化活性。
发明内容
本发明公开了一个新的组合物82092202050618,该组合物由化合物III和化合物IV组成,该组合物中化合物III和化合物IV的质量百分数分别为65%和35%。
本发明公开的组合物可以制成药学上可接受的盐或药学上可接受的载体。
药效学实验表明,本发明的组合物具有较好的抗胰腺纤维化作用。本发明的药学上可接受的盐具有同样的药效。
以下通过实施例对本发明作进一步详细的说明,但本发明的保护范围不受具体实施例的任何限制,而是由权利要求加以限定。
具体实施方式
实施例1化合物SchiglautoneA的制备
化合物SchiglautoneA(I)的制备方法参照Fan-YuMeng等人发表的文献(Fan-YuMengetal.,2011.SchiglautoneA,aNewTricyclicTriterpenoidwithaUnique6/7/9-FusedSkeletonfromtheStemsofSchisandraglaucescens.OrganicLetters13(2011)1502–1505)的方法。
实施例2SchiglautoneA的O-溴乙基衍生物(II)的合成
将化合物I(502mg,1.00mmol)溶于15mL苯,向溶液中加入四丁基溴化铵(TBAB)(0.08g),1,2-二溴乙烷(7.520g,40.00mmol)和6mL的50%氢氧化钠溶液。混合物在35摄氏度搅拌8h。8h之后将反应液倒入冰水中,立即用二氯甲烷萃取两次,合并有机相溶液。然后对有机相溶液依次用水和饱和食盐水洗涤3次,再用无水硫酸钠干燥,最后减压浓缩去除溶剂得到产物粗品。产物粗品用硅胶柱层析纯化(流动相为:石油醚/丙酮=100:1.0,v/v),收集棕色集中洗脱带并挥去溶剂即得到化合物II的棕色粉末(508mg,71%)。
1HNMR(500MHz,DMSO-d6)δ13.40(s,1H),6.10(s,1H),5.63(s,1H),5.53(s,1H),3.85(d,J=11.2Hz,4H),3.52(d,J=10.8Hz,4H),2.96(s,1H),2.20(s,1H),2.16(s,2H),2.00(s,1H),1.84(d,J=13.9Hz,4H),1.69(s,1H),1.58(dd,J=22.2,8.5Hz,4H),1.51(s,1H),1.47(s,1H),1.26(dd,J=9.1,4.4Hz,4H),1.21(s,1H),1.08–0.98(m,4H),0.96-0.94(m,9H),0.94-0.85(m,6H).
13CNMR(125MHz,DMSO-d6)δ211.46(s),209.14(s),170.06(s),161.12(s),143.51(s),132.01(s),127.77(s),85.96(s),82.40(s),70.19(s),69.10(s),57.14(s),52.73(s),51.90(s),45.77(s),40.67(s),38.57(s),38.32(s),35.04(s),33.55(s),33.27(s),29.85(s),28.98(s),26.71(s),25.50(s),24.05(s),22.31(s),21.06(s),20.56(s),20.00(s),18.69(s),18.11(s),15.07(s).
HRMS(ESI)m/z[M-H]-calcdforC34H51Br2O6:715.2032;found715.2027.
实施例3SchiglautoneA的O-(四氢吡咯基)乙基衍生物(III)的合成
将化合物II(358mg,0.5mmol)溶于15mL乙腈当中,向其中加入无水碳酸钾(690mg,5.0mmol),碘化钾(168mg,1.0mmol)和吡咯烷(2840mg,40mmol),混合物加热回流6h。反应结束后将反应液倒入冰水中,用等量二氯甲烷萃取4次,合并有机相。依次用水和饱和食盐水洗涤合并之后的有机相,再用无水硫酸钠干燥,减压浓缩去除溶剂得到产物粗品。产物粗品用硅胶柱层析纯化(流动相为:石油醚/丙酮=100:1.5,v/v),收集棕色集中洗脱带并挥去溶剂即得到化合物III的棕色粉末(215.8mg,62%)。
1HNMR(500MHz,DMSO-d6)δ13.06(s,1H),6.10(s,1H),5.65(d,J=43.0Hz,2H),3.61(s,2H),3.52(s,2H),3.01(s,1H),2.77(s,1H),2.67(d,J=14.2Hz,4H),2.51(s,8H),2.37(s,2H),2.23(s,1H),1.92–1.81(m,5H),1.73(s,1H),1.68(d,J=3.5Hz,8H),1.61–1.53(m,4H),1.44(d,J=64.7Hz,2H),1.28(dd,J=21.0,9.0Hz,4H),1.08–0.98(m,4H),0.96(d,J=20.0Hz,6H),0.94(d,J=20.0Hz,3H),0.90(d,J=20.0Hz,3H),0.86(d,J=20.0Hz,3H).
13CNMR(125MHz,DMSO-d6)δ211.57(s),209.27(s),170.21(s),161.23(s),143.64(s),132.16(s),127.88(s),86.09(s),82.55(s),67.09(s),66.24(s),57.29(s),54.51(d,J=17.1Hz),52.85(s),52.04(s),45.90(s),40.79(s),38.71(s),38.45(s),35.16(s),33.69(s),29.96(s),29.11(s),26.86(s),25.61(s),25.33(s),24.19(s),22.44(s),21.18(s),20.70(s),20.13(s),18.81(s),18.25(s),15.20(s).
HRMS(ESI):m/z[M+H]+calcdforC42H69N2O6:697.5156;found:697.5151。
实施例4SchiglautoneA的O-(哌嗪基)乙基衍生物(IV)的合成
将化合物II(358mg,0.5mmol)溶于30mL乙腈当中,向其中加入无水碳酸钾(1380mg,10.0mmol),碘化钾(336mg,2.0mmol)和无水哌嗪(3446mg,40mmol),混合物加热回流6h。反应结束后将反应液倒入冰水中,用等量二氯甲烷萃取3次,合并有机相。依次用水和饱和食盐水洗涤合并之后的有机相,再用无水硫酸钠干燥,减压浓缩去除溶剂得到产物粗品。产物粗品用硅胶柱层析纯化(流动相为:石油醚/丙酮=100:0.5,v/v),收集淡棕色集中洗脱带即得到化合物IV的淡棕色固体(261.4mg,72%)。
1HNMR(500MHz,DMSO-d6)δ13.14(s,1H),6.14(s,1H),5.57(d,J=21.3Hz,2H),3.59(s,2H),3.52(s,2H),3.01(s,1H),2.68(s,8H),2.57(d,J=3.3Hz,4H),2.39(s,2H),2.34(d,J=4.3Hz,8H),2.33(s,1H),2.22(s,1H),1.88(d,J=11.7Hz,4H),1.79(s,1H),1.73(s,1H),1.66(s,1H),1.60–1.53(m,3H),1.50(s,1H),1.37(s,1H),1.28(dd,J=21.3,8.7Hz,4H),1.07(d,J=6.6Hz,2H),1.06(s,1H),0.99(t,J=12.0Hz,3H),0.96(t,J=12.5Hz,6H),0.94(t,J=12.5Hz,3H),0.88(d,J=20.0Hz,6H).
13CNMR(125MHz,DMSO-d6)δ211.55(s),209.25(s),170.19(s),161.22(s),143.62(s),132.14(s),127.86(s),86.08(s),82.53(s),67.07(s),66.22(s),57.27(s),54.54(s),54.24(s),52.84(s),52.00(s),45.88(s),45.35(s),40.76(s),38.67(s),38.45(s),35.12(s),33.65(s),29.96(s),29.07(s),26.83(s),25.61(s),24.15(s),22.43(s),21.16(s),20.68(s),20.11(s),18.76(s),18.23(s),15.18(s).
HRMS(ESI):m/z[M+H]+calcdforC42H71N4O6:727.5374;found:727.5379。
实施例5组合物抗胰腺纤维化活性
1材料
1.1动物Wistar大鼠,雄性,体重180-200g。
1.2组合物82092202050618剂量:0.9mg/kg。
组合物82092202050618的制备:将研磨之后过200目网的65mg化合物III的粉末和研磨之后过200目网的35mg化合物IV的粉末装入带盖的小管中并用涡轮搅拌仪混合即得到100mg组合物82092202050618,使用时用水溶解这100mg的组合物即得到组合物82092202050618的溶液。
2实验方法
2.1造模方法:Wistar大鼠以腹腔注射dl-乙硫氨酸250mg/天,连续2个月,可出现胰脏腺细胞减少,间质内脂肪及结缔组织的增生。
2.2分组及给药方法
模型大鼠随机分为模型组,组合物0.9mg/kg组、化合物III0.9mg/kg组和化合物IV0.9mg/kg组,另设空白对照组。给药组于造模开始后给药,口服连续30天;60天时解剖动物。
2.3检测指标
2.3.1实验结束时取胰脏称重。
2.3.2胰脏羟脯氨酸含量测定取100mg样本在水中匀浆,110℃10NHCl中水解20小时。HCl用氮气挥发,水解产物用双蒸水溶解后过滤。取0.5ml液体与3ml枸橼酸磷酸缓冲液(0.15M枸橼酸加0.6M磷酸氢二钠)和0.5ml溶于9M磷酸的1M过碘酸混合。加1.75ml提取缓冲液(5份甲苯:5份2-甲基-1-丙醇:2份1-丙醇),震荡30min,离心。组织相(0.6ml)与Ehrlich,s试剂混合放置15min。在565nm测定吸收度,用4-羟-1-脯氨酸制作标准曲线计算浓度,含量以ug/g组织表示。
2.3.3组织学检查胰脏组织用10%福尔马林固定,石蜡包埋,染色后镜检。对纤维化情况评分(0-3分)。
3结果
3.1组合物对大鼠胰脏脏器系数的影响
实验结束时,将大鼠处死、解剖,称量体重和胰脏重并计算其与体重的比值(胰脏脏器系数),结果见表1。组合物对胰脏脏器系数的影响,与模型组比较有显著性差异。化合物III和化合物IV对胰脏脏器系数的影响,与模型组比较无显著性差异。
表1
*表示p<0.05,与模型组比较
3.2胰脏羟脯氨酸含量测定
实验结束时,对各组大鼠进行肺部羟脯氨酸含量测定,结果如表2。组合物对羟脯氨酸含量的影响,与模型组比较有显著性差异。化合物III和化合物IV对羟脯氨酸含量的影响,与模型组比较无显著性差异。
表2
*表示p<0.05,与模型组比较
3.3组织学检查
实验结束时,将大鼠处死、解剖;标本常规包埋、固定、HE染色,镜检。
结果:模型组第60天可见胰导管周围严重炎症反应;嗜中粒细胞核淋巴细胞浸润,间质水肿,出血以及偶见胰泡细胞坏死;胰泡细胞消失位置及胰泡间出现纤维化。
组合物可减少炎症反应和纤维化。评分结果见表3。组合物对评分的影响,与模型组比较有显著性差异。
表3
*表示p<0.05,与模型组比较;空白对照组的炎症细胞浸润和纤维化评分都为0.
结论:本发明通过组合物对大鼠胰腺纤维化的影响,证实了组合物具有抗胰腺纤维化的作用。因此,组合物可作为活性成分用于制备抗胰腺纤维化的药物。而化合物III和化合物IV无此活性,不能用于制备抗胰腺纤维化的药物。
实施例6本发明所涉及组合物82092202050618片剂的制备
取2克组合物82092202050618,加入制备片剂的常规辅料18克,混匀,常规压片机制成100片。
实施例7本发明所涉及组合物82092202050618胶囊的制备
取2克组合物82092202050618,加入制备胶囊剂的常规辅料如淀粉18克,混匀,装胶囊制成100粒。
Claims (6)
1.一种组合物82092202050618,其特征为该组合物由化合物III和化合物IV组成,该组合物中化合物III和化合物IV的质量百分数分别为65%和35%,
2.如权利要求1所述的组合物82092202050618的制备方法,其特征为:将化合物III的粉末和化合物IV的粉末按照质量百分数分别为65%和35%充分混合。
3.一种如权利要求1所述的组合物82092202050618在治疗胰腺纤维化药物中的应用。
4.如权利要求3所述的组合物82092202050618在治疗胰腺纤维化药物中的应用,其特征为:所述组合物逆转胰腺纤维化所引起的胰脏脏器系数下降。
5.如权利要求3所述的组合物82092202050618在治疗胰腺纤维化药物中的应用,其特征为:所述组合物逆转胰腺纤维化所引起的羟脯氨酸含量升高。
6.如权利要求3所述的组合物82092202050618在治疗胰腺纤维化药物中的应用,其特征为:所述组合物逆转胰腺纤维化所引起的炎症细胞浸润升高。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510662966.6A CN105343089A (zh) | 2015-10-14 | 2015-10-14 | 组合物及其在预防或治疗胰腺纤维化药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510662966.6A CN105343089A (zh) | 2015-10-14 | 2015-10-14 | 组合物及其在预防或治疗胰腺纤维化药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105343089A true CN105343089A (zh) | 2016-02-24 |
Family
ID=55319251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510662966.6A Pending CN105343089A (zh) | 2015-10-14 | 2015-10-14 | 组合物及其在预防或治疗胰腺纤维化药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105343089A (zh) |
-
2015
- 2015-10-14 CN CN201510662966.6A patent/CN105343089A/zh active Pending
Non-Patent Citations (1)
Title |
---|
FAN-YU MENG等: "Schiglautone A,a New Tricyclic Triterpenoid with a Unique 6/7/9-Fused Skeleton from the Stems of Schisandra glaucescens", 《ORGANIC LETTERS》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104147019A (zh) | 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
CN105232508A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN104825466A (zh) | 闭花木酮的o-(苯并咪唑基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
CN105193791A (zh) | 组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105343089A (zh) | 组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105250312A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105287555A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105343081A (zh) | 组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105287569A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105267190A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN104739846A (zh) | 闭花木酮的o-(1h-四氮唑基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
CN105343100A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105193817A (zh) | 组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105078984A (zh) | 组合物71083001030522及其在预防或治疗胰腺纤维化药物中的应用 | |
CN105250273A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
CN104800213A (zh) | Daphmalenine A衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
CN104922122A (zh) | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
CN106038553A (zh) | SChiglautone A衍生物的组合物用于制备防治胰腺纤维化药物 | |
CN106074529A (zh) | 阿掏比克酸三唑基与1h‑四氮唑基衍生物的组合物用于制备防治胰腺纤维化药物 | |
CN105853427A (zh) | Virosaine A的哌嗪基和咪唑基衍生物的组合物在预防或治疗胰腺纤维化药物中的应用 | |
CN106074516A (zh) | 阿掏比克酸苯并咪唑基与二羟乙胺基衍生物的组合物用于制备防治胰腺纤维化药物 | |
CN106074480A (zh) | Artalbic acid的衍生物的组合物用于制备防治胰腺纤维化药物 | |
CN106420719A (zh) | Atropurpuran衍生物组合物在预防或治疗胰腺纤维化药物中的应用 | |
CN105878252A (zh) | Virosaine A的四氢吡咯基和吗啉基衍生物的组合物在预防或治疗胰腺纤维化药物中的应用 | |
CN106176733A (zh) | Schiglautone A的衍生物组合物在预防或治疗胰腺纤维化药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160224 |
|
RJ01 | Rejection of invention patent application after publication |